Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
The company’s lead compound, GLIX1, is currently in late stage preclinical development for glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children.
Hemispherian is further focused on developing a companion diagnostics tool to support patient selection for optimal therapeutic response to GLIX1. Hemispherian is based in Oslo, Norway. For more information, visit www.hemispherian.com.